WASHINGTON — The $100,000 monthly fee Novartis paid a company set up by President Trump’s personal attorney to help it better understand “U.S. healthcare policy matters” in the Trump era is almost four times more than it paid any actual outside lobbyist in the same time period.

None of the contracts for the nearly four dozen external lobbyists Novartis employs to help explain and advocate on health care policy issues came close to the amounts paid Essential Consultants LLC, according to a STAT review of the Swiss drug maker’s 2017 and 2018 filings.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe, Erin, that the actual amount is still rather fascinating -and you rounded it off!! Especially if Jose Jimenez (the then-current CEO) was in the loop, why make it precisely $99,980/ month – not the even $100,000 you wrote above? What did shaving the $20 prevent?
    “Inquiring minds want to know” …. and, frankly, so should you, although Pharmalot/ Ed Silverman seems to have the point on this one.)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy